Atom Investors’s Cullinan Oncology CGEM Stock Holding History

Atom Investors’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-120,109	Closed	-$1.23M	–	304
2023 Q1	$1.23M	Buy	120,109 +12,916	+12%	+$142K	0.67%	32
2022 Q4	$1.13M	Buy	107,193 +26,322	+33%	+$320K	0.57%	47
2022 Q3	$1.04M	Sell	80,871 -16,009	-17%	-$216K	0.36%	83
2022 Q2	$1.24M	Buy	+96,880	New	+$1.1M	0.54%	52

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Atom Investors's CGEM Position: Q2 2023 in Review

Atom Investors sold out of Cullinan Oncology (CGEM) in Q2 2023, closing a stake of 120,109 shares — an estimated $1.23M sold.

Atom Investors first reported a position in CGEM in Q2 2022 and held it in 4 quarters. The position peaked at $1.24M in Q2 2022. 106 funds tracked by Wall St. Rank hold CGEM as of Q2 2023.

Atom Investors reported no remaining Cullinan Oncology position as of Q2 2023 after selling out during the quarter.
Atom Investors sold 120,109 Cullinan Oncology shares in Q2 2023, an estimated $1.23M.
Atom Investors first reported a position in Cullinan Oncology in Q2 2022 and held it in 4 quarters.
Atom Investors's Cullinan Oncology position peaked at $1.24M in Q2 2022.
106 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2023.

Based on Atom Investors's 13F filing for Q2 2023, filed 14 Aug 2023.